Charles Schwab Investment Management Inc Xeris Biopharma Holdings, Inc. Call Options Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding XERS
# of Institutions
143Shares Held
57.3MCall Options Held
87.6KPut Options Held
80.4K-
Black Rock Inc. New York, NY9.96MShares$22.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.61MShares$17.1 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$11.5 Million69.8% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.17MShares$9.37 Million1.51% of portfolio
-
State Street Corp Boston, MA3.22MShares$7.23 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $306M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...